CVS, Walgreens Announce $10 Billion Opioid Settlements
WEDNESDAY, Nov. 2, 2022 (HealthDay News) — Years of litigation over the opioid epidemic could end soon, as the national pharmacy chains CVS and Walgreens announced Wednesday that each company has agreed to a nearly $5 billion settlement. While neithe…
Learn MoreNeoadjuvant Combo Immunotherapy Studied in Resectable Melanoma
FRIDAY, Oct. 28, 2022 (HealthDay News) — For patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab and nivolumab combination immunotherapy results in a 57 percent pathologic complete response rate, a…
Learn MoreHaloperidol Not Beneficial for ICU Patients With Delirium
FRIDAY, Oct. 28, 2022 (HealthDay News) — Treatment with haloperidol does not yield a greater number of days alive and out of the hospital at 90 days than placebo among patients with delirium admitted to the intensive care unit, according to a study p…
Learn MoreDisparities ID’d in Dispensing of Oral Antivirals for COVID-19
THURSDAY, Oct. 27, 2022 (HealthDay News) — Disparities are seen in the dispensing of oral antiviral drugs for treatment of COVID-19 based on social vulnerability zip codes, according to research published in the Oct. 28 issue of the U.S. Centers for…
Learn MoreMany Parents Have Unused Prescription Meds at Home
THURSDAY, Oct. 27, 2022 (HealthDay News) — Parents commonly keep medicines long after they are expired or no longer needed in their home, according to the results of a survey released by the C.S. Mott Children’s Hospital National Poll on Children’s …
Learn MoreIDSA: Long-Term Follow-Up Reported for Early Initiation of ART in HIV
TUESDAY, Oct. 25, 2022 (HealthDay News) — Initiating antiretroviral treatment (ART) early in the course of HIV infection results in better outcomes compared with deferred initiation, although the difference in ongoing excess risk is reduced with long…
Learn MoreNivolumab Promising for Treatment of Advanced Cutaneous SCC
MONDAY, Oct. 24, 2022 (HealthDay News) — For advanced cutaneous squamous cell carcinoma (aCSCC), first-line treatment with nivolumab shows robust antitumor activity and good tolerability, according to a study published online Oct. 24 in Cancer.Rodrig…
Learn MoreEffectiveness of Antipsychotics Dips for Women After Age 45 Years
MONDAY, Oct. 24, 2022 (HealthDay News) — Antipsychotic effectiveness declines in women after the age of 45 years, according to a study published online Oct. 5 in Schizophrenia Bulletin.Iris E. Sommer, M.D., Ph.D., from the University Medical Center G…
Learn MoreTopical Cream May Restore Skin Pigmentation in People With Vitiligo
MONDAY, Oct. 24, 2022 (HealthDay News) — For the millions of people who live with vitiligo, a disease that robs the skin of its natural color, a newly approved cream called ruxolitinib (Opzelura) is quickly becoming a game changer.The U.S. Food and D…
Learn MoreRuxolitinib Cream Results in Greater Repigmentation in Vitiligo
THURSDAY, Oct. 20, 2022 (HealthDay News) — For patients with vitiligo, ruxolitinib cream results in greater repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the New England Journal of Medicine….
Learn More